SMARCD2 and breast carcinoma: SMARCD2, BCL7C and SS18L1 are amplified in 6%–8% of breast cancer patients from the TCGA and METABRIC breast cancer patient cohorts (Figure 4) (Curtis et al., 2012; Weinstein et al., 2013).